Titlebook: Antitrust in Pharmaceutical Markets & Geographical Rules of Origin; Pierre Kobel,Pranvera K?llezi,Bruce Kilpatrick Book 2017 The Editor(s)

estradiol

書目名稱Antitrust in Pharmaceutical Markets & Geographical Rules of Origin影響因子(影響力)




書目名稱Antitrust in Pharmaceutical Markets & Geographical Rules of Origin影響因子(影響力)學(xué)科排名




書目名稱Antitrust in Pharmaceutical Markets & Geographical Rules of Origin網(wǎng)絡(luò)公開度




書目名稱Antitrust in Pharmaceutical Markets & Geographical Rules of Origin網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Antitrust in Pharmaceutical Markets & Geographical Rules of Origin被引頻次




書目名稱Antitrust in Pharmaceutical Markets & Geographical Rules of Origin被引頻次學(xué)科排名




書目名稱Antitrust in Pharmaceutical Markets & Geographical Rules of Origin年度引用




書目名稱Antitrust in Pharmaceutical Markets & Geographical Rules of Origin年度引用學(xué)科排名




書目名稱Antitrust in Pharmaceutical Markets & Geographical Rules of Origin讀者反饋




書目名稱Antitrust in Pharmaceutical Markets & Geographical Rules of Origin讀者反饋學(xué)科排名

folliculitis

Austrial Act 2005 (hereafter referred to as “Cartel Act”) and the Austrian Competition Act 2002 (hereafter referred to as “Competition Act”). The Competition Act complements the Cartel Act and contains rules on the Federal Competition Authority (., hereafter referred to as FCA), its tasks, and some procedu

嚴(yán)厲譴責(zé)

新星

Conducive

Hungaryrian Competition Authority. However, certain provisions of Hungarian pharmaceutical regulation are relevant from a competition law viewpoint (e.g. regulation promoting generic entry and prescribing a domestic supply obligation). The cases investigated by the Hungarian Competition Authority concern b

增長(zhǎng)

Italyicle 2, on anticompetitive agreements, and Article 3, on abuse of dominant position, of Law 287/90 (the “Italian Antitrust Law” or the IAL), which contain the same principles of Articles 101 and 102 TFEU.

optic-nerve

Acquired

Polandtion law. We consider the general legislative framework and specific provisions of pharmaceutical law concerning competition law aspects, as well as the enforcement of competition law in the pharmaceutical sector. We also reflect upon the interplay between competition law and intellectual property,

財(cái)主

Swedenompetition rules or specific sectorial non-competition legislation. Swedish Competition Law enforcement has been, so far, sporadic at best, and has not addressed particularly “sexy” issues such as hardcore cases of refusal to license and pay-for-delay settlement agreements. Instead, the Swedish non-

periodontitis